cover
Article Per Year (5 Year)
All
Home Page
OAI Link
Editorial Team
Contact
Reviewer
Google Scholar
Contact Name
-
Contact Email
-
Phone
-
Journal Mail Official
-
Editorial Address
-
Location
Kota yogyakarta,
Daerah istimewa yogyakarta
INDONESIA
Indonesian Journal of Cancer Chemoprevention
Published by Indonesian Society for Cancer Chemoprevention
ISSN : 23558989     EISSN : 20880197     DOI : -
Core Subject : Health, Science,
Biochemistry, Genetics & Molecular Biology Medicine & Pharmacology
Indonesian Journal of Cancer Chemoprevention (IJCC) is an open access, peer-reviewed, triannual journal devoted to publishing articles on Cancer Chemoprevention including Experimental and Clinical Pharmacology, especially concerning Anti-Oxidants, Anti-Aging, Anti-Inflammation, Anti-Angiogenesis, and Anti-Carcinogenesis; Cancer Detection; Stem Cell Biology; Immunology; in vitro and in silico Exploration of Chemopreventive Mechanism; and Natural Products.
Arjuna Subject : -
Articles 334 Documents
 30   31   32   33   34 
Rosmarinic Acid from Orthosiphon aristatus Potentially Targets Estrogen Receptor-Alpha in Breast Cancer: In-silico Study Qurrotaayun, Ghina Alya Putri; Sitompul, Joy Elizabeth Nauli; Fadhilah, Naya; Pramudita, Fransisca Widi; Putri, Nazwa Septiriana; Muljono, Fajar Oktavian; Fardhan, Firghi Muhammad; Novitasari, Dhania
Indonesian Journal of Cancer Chemoprevention Vol 15, No 2 (2024)
Publisher : Indonesian Society for Cancer Chemoprevention

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.14499/indonesianjcanchemoprev15iss2pp150-161

Abstract

Breast cancer is the most common cancer among women. Tamoxifen, a widely used estrogen receptor-alpha (ER-α) inhibitor, is effective but often causes side effects, necessitating the search for alternative inhibitors from natural sources. Ortosiphon aristatus, also known as cat's whiskers, is a medicinal plant traditionally valued for its anti-inflammatory and antioxidant properties. Recent studies suggest its bioactive compounds may exhibit anticancer activity by inducing apoptosis in cancer cell lines. This study explores the potential of O. aristatus metabolites as ER-α inhibitors using computational approaches. Nine metabolites were assessed for their physicochemical properties based on Lipinski’s rule of five and ADMET predictions, followed by pharmacophore-based virtual screening with LigandScout and molecular docking with AutoDock. The results showed that all tested compounds complied with Lipinski’s rule, and most met ADMET criteria. Among these, rosmarinic acid was identified as one of the hit compounds based on pharmacophore screening, exhibiting binding interactions comparable to 4-hydroxytamoxifen with the ER-α amino acid residues HIS524 and GLY521. It also demonstrated a binding energy of -8.02 kcal/mol and a low inhibition constant (Ki) of 1.31 μM. These findings highlight the potential of O. aristatus and rosmarinic acid for further evaluation as candidates against ER-α in breast cancer cells.Keywords: breast cancer, estrogen receptor-alpha, Orthosiphon aristatus, in silico.
Molecular Insights into Breast Cancer Treatment: An Integrated Approach of Network Pharmacology and Component Analysis for Lansium parasiticum Bark Extract Mutiah, Roihatul; Annisa, Rahmi; Zahiro, Syayida Roisatus
Indonesian Journal of Cancer Chemoprevention Vol 15, No 2 (2024)
Publisher : Indonesian Society for Cancer Chemoprevention

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.14499/indonesianjcanchemoprev15iss2pp96-107

Abstract

Medicinal plants containing multi-components have the potential for multi-target genes, multi-pathways, and various effects on diverse diseases. With the increasing technological advancements, understanding the complex interactions between multi-component substances and biological systems is becoming more crucial. In this context, conventional experimental research might have limitations as it typically focuses on the impact of one component on one gene. The objective of this research is to identify compounds in the bark extract of Lansium parasiticum and elucidate the molecular mechanisms of these compounds in inhibiting the progression of breast cancer cells using a network pharmacology approach. Compound identification in Lansium parasiticum bark extract (LPBE) has been conducted using Liquid Chromatography Tandem Mass Spectrophotometry (LC-MS/MS) technique. ADMET predictions were utilized to determine the absorption and bioavailability profiles. A network pharmacology approach employing Cytoscape 3.9.1, GeneCards, Disgenet, STRING 2.0.0, SRplot, and Kyoto Encyclopedia of Genes and Genomes (KEGG) was used to predict the anti-cancer molecular mechanisms of these compounds. Seventeen active compounds have been successfully identified via LC-MS/MS. Among these, the compounds Moronic Acid, 4-Morpholineacetic Acid, and Ursolic Aldehyde were found in the highest concentrations. The results of the network pharmacology analysis indicate that the compounds in LPBE are involved in three potential pathways for breast cancer treatment: the NF-κß signaling pathway (hsa 04064), microRNA in cancer (hsa05206), and apoptosis (hsa04210). Target genes implicated in these pathways include BAX, BCL2, TNF-α, PARP1, STAT3, NOTCH1, and NF-κß1. It can be concluded that LPBE contains compounds with potential for treating breast cancer, as they are predicted to interact with relevant target pathways and genes. Therefore, further research is highly recommended, particularly in the development of drugs for breast cancer.Keywords: apoptosis, microRNA, NF-κß, TNF-α, STAT3.
Nanotechnology in Cancer Treatment: Innovative Approaches to Overcoming Drug Resistance in Tumors Eskandar, Kirolos
Indonesian Journal of Cancer Chemoprevention Vol 15, No 2 (2024)
Publisher : Indonesian Society for Cancer Chemoprevention

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.14499/indonesianjcanchemoprev15iss2pp162-174

Abstract

Nanotechnology has emerged as a groundbreaking approach in oncology, offering innovative solutions to one of the most significant challenges in cancer treatment: drug resistance. This literature review explores the role of nanotechnology in overcoming multidrug resistance (MDR) in tumors, focusing on the use of nanoparticles for targeted drug delivery, gene therapy, and immunotherapy. By penetrating biological barriers and modulating the tumor microenvironment, nanocarriers enhance the efficacy of anticancer agents while minimizing side effects. Additionally, this review provides a comprehensive analysis of recent clinical trials, offering insights into the real-world effectiveness of nanotechnology-based treatments. Ethical, regulatory challenges, and nanotoxicity are discussed to ensure the safe translation of nanomedicine to clinical practice. The review concludes with future directions in personalized nanomedicine, highlighting nanotechnology’s transformative potential in revolutionizing cancer treatment and improving patient outcomes by addressing the pervasive issue of drug resistance.Keywords: nanotechnology, drug resistance, nanoparticles, targeted drug delivery, cancer therapy.
Structure-based Virtual Screening, and Design of Some Lead Compounds as Inhibitors of Kras-G12D of Pancreatic Cancer Ovaku, Idris Momohjimoh; Abechi, Stephen Eyije; Shallangwa, Gideon Adamu; Umar, Abdullahi Bello; Uzairu, Adamu
Indonesian Journal of Cancer Chemoprevention Vol 15, No 2 (2024)
Publisher : Indonesian Society for Cancer Chemoprevention

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.14499/indonesianjcanchemoprev15iss2pp108-126

Abstract

Pancreatic cancer is an abnormal cell growth in the pancreas. In 2021, approximately 60,430 individuals were diagnosed in the USA, with the annual increasing incidence rates. Pancreatic cancer is anticipated to become the second leading cause of cancer mortality by 2030. This escalating challenge has prompted a search for innovative therapeutic agents. Virtual screening, a computational technique, was employed to discover novel drug-like compounds from a diverse set of 30 chemical compounds, sourced from the PubChem database. These compounds were evaluated based on some important properties, including pharmacokinetics, lipophilicity, drug-likeness, water-solubility, and physicochemical characteristics. Seventeen compounds emerged as promising candidates for pancreatic cancer treatment. Subsequent molecular docking studies focused on the Kras-G12D protein target and identified Ligand 18 as the leading candidate, exhibiting a binding energy (BE) of -10.5 kcal mol-1 and extensive interactions with the target protein. Additionally, a newly designed compound, D4, displayed an even higher BE of -10.8 kcal mol-1, fitting more effectively into the protein's binding site than existing drugs like Gemcitabine and Irinotecan. All newly designed compounds met the five scientists' rule, indicating favorable drug-likeness and bioavailability. These findings pave the way for developing a new generation of less toxic therapeutic compounds for pancreatic cancer treatment.Keywords: virtual screening, binding energy, kras-G12D, pancreatic cancer, designed compounds.

Page 34 of 34 | Total Record : 334

 30   31   32   33   34 

Filter by Year

2010 2024


Reset
Filter By Issues
All Issue Vol 15, No 2 (2024) Vol 15, No 1 (2024) Vol 14, No 3 (2023) Vol 14, No 2 (2023) Vol 14, No 1 (2023) Vol 13, No 3 (2022) Vol 13, No 2 (2022) Vol 13, No 1 (2022) Vol 12, No 3 (2021) Vol 12, No 2 (2021) Vol 12, No 1 (2021) Vol 11, No 3 (2020) Vol 11, No 2 (2020) Vol 11, No 1 (2020) Vol 10, No 3 (2019) Vol 10, No 2 (2019) Vol 10, No 1 (2019) Vol 9, No 3 (2018) Vol 9, No 2 (2018) Vol 9, No 1 (2018) Vol 8, No 3 (2017) Vol 8, No 2 (2017) Vol 8, No 1 (2017) Vol 7, No 3 (2016) Vol 7, No 2 (2016) Vol 7, No 1 (2016) Vol 6, No 3 (2015) Vol 6, No 2 (2015) Vol 6, No 1 (2015) Vol 4, No 1 (2013) Vol 3, No 3 (2012) Vol 3, No 3 (2012) Vol 3, No 2 (2012) Vol 3, No 2 (2012) Vol 3, No 1 (2012) Vol 3, No 1 (2012) Vol 2, No 3 (2011) Vol 2, No 3 (2011) Vol 2, No 2 (2011) Vol 2, No 2 (2011) Vol 2, No 1 (2011) Vol 2, No 1 (2011) Vol 1, No 2 (2010) Vol 1, No 2 (2010) Vol 1, No 1 (2010) Vol 1, No 1 (2010) More Issue